131 related articles for article (PubMed ID: 9918418)
1. Long-term outcome of treatment with dacarbazine, cisplatin, interferon-alpha and intravenous high dose interleukin-2 in poor risk melanoma patients.
Proebstle TM; Fuchs T; Scheibenbogen C; Sterry W; Keilholz U
Melanoma Res; 1998 Dec; 8(6):557-63. PubMed ID: 9918418
[TBL] [Abstract][Full Text] [Related]
2. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.
Keilholz U; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; Thomas J; Proebstle TM; Schmittel A; Schadendorf D; Velu T; Negrier S; Kleeberg U; Lehman F; Suciu S; Eggermont AM
J Clin Oncol; 2005 Sep; 23(27):6747-55. PubMed ID: 16170182
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of dacarbazine, cisplatin, interferon-alpha and high-dose interleukin-2 in 'poor-risk' metastatic melanoma.
Proebstle TM; Scheibenbogen C; Sterry W; Keilholz U
Eur J Cancer; 1996 Aug; 32A(9):1530-3. PubMed ID: 8911113
[TBL] [Abstract][Full Text] [Related]
4. Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group.
Punt CJ; Suciu S; Gore MA; Koller J; Kruit WH; Thomas J; Patel P; Lienard D; Eggermont AM; Keilholz U
Eur J Cancer; 2006 Nov; 42(17):2991-5. PubMed ID: 17023156
[TBL] [Abstract][Full Text] [Related]
5. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.
Atzpodien J; Lopez Hänninen E; Kirchner H; Franzke A; Körfer A; Volkenandt M; Duensing S; Schomburg A; Chaitchik S; Poliwoda H
Eur J Cancer; 1995 Jun; 31A(6):876-81. PubMed ID: 7646914
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases.
Buzaid AC; Colome M; Bedikian A; Eton O; Legha SS; Papadopoulos N; Plager C; Ross M; Lee JE; Mansfield P; Rice J; Ring S; Lee JJ; Strom E; Benjamin R
Melanoma Res; 1998 Dec; 8(6):549-56. PubMed ID: 9918417
[TBL] [Abstract][Full Text] [Related]
7. Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 and interferon-alpha in patients with metastatic melanoma.
González Cao M; Malvehy J; Martí R; Conill C; Sánchez M; Martín M; Carrera C; Herrero J; Gascón P; Mellado B; Castel T; Puig S
Melanoma Res; 2006 Feb; 16(1):59-64. PubMed ID: 16432457
[TBL] [Abstract][Full Text] [Related]
8. Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma.
Thompson JA; Gold PJ; Markowitz DR; Byrd DR; Lindgren CG; Fefer A
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S29-34. PubMed ID: 9457390
[TBL] [Abstract][Full Text] [Related]
9. Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a.
Hoffmann R; Müller I; Neuber K; Lassmann S; Buer J; Probst M; Oevermann K; Franzke A; Kirchner H; Ganser A; Atzpodien J
Br J Cancer; 1998 Oct; 78(8):1076-80. PubMed ID: 9792153
[TBL] [Abstract][Full Text] [Related]
10. Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients.
Ridolfi L; Fiorentini G; Guida M; Michiara M; Freschi A; Aitini E; Ballardini M; Bichisao E; Ridolfi R;
Melanoma Res; 2009 Apr; 19(2):100-5. PubMed ID: 19262411
[TBL] [Abstract][Full Text] [Related]
11. A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolomide (Temodal), interferon-alfa and interleukin-2 for metastatic melanoma: a phase II study.
Ron IG; Sarid D; Ryvo L; Sapir EE; Schneebaum S; Metser U; Asna N; Inbar MJ; Safra T
Melanoma Res; 2006 Feb; 16(1):65-9. PubMed ID: 16432458
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
Johnston SR; Constenla DO; Moore J; Atkinson H; A'Hern RP; Dadian G; Riches PG; Gore ME
Br J Cancer; 1998 Apr; 77(8):1280-6. PubMed ID: 9579834
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
Dillman RO; Soori G; Wiemann MC; Schulof R; Dobbs TW; Ruben RH; DePriest CB; Church C
Cancer Biother Radiopharm; 2000 Oct; 15(5):487-94. PubMed ID: 11155820
[TBL] [Abstract][Full Text] [Related]
14. Complex combination biochemotherapy regimen in advanced metastatic melanoma in a non-intensive care unit: toxicity or benefit?
Hofmann MA; Sterry W; Trefzer U
Jpn J Clin Oncol; 2007 Mar; 37(3):224-9. PubMed ID: 17472972
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of biochemotherapy for the treatment of metastatic malignant melanoma.
Gibbs P; Iannucci A; Becker M; Allen J; O'Driscoll M; McDowell K; Williams P; Rosse P; Murphy J; Gonzalez R
Melanoma Res; 2000 Apr; 10(2):171-9. PubMed ID: 10803718
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study.
Dorval T; Négrier S; Chevreau C; Avril MF; Baume D; Cupissol D; Oskam R; de Peuter R; Vinke J; Herrera A; Escudier B
Cancer; 1999 Mar; 85(5):1060-6. PubMed ID: 10091789
[TBL] [Abstract][Full Text] [Related]
17. Concurrent chemobiotherapy with cisplatin, dacarbazine, decrescendo interleukin-2 and interferon alpha2b in patients with metastatic melanoma.
Bar J; Yerushalmi R; Shapira-Frummer R; Kutchuk I; Sulkes A; Gutman H; Catane R; Schachter J
Oncol Rep; 2008 Dec; 20(6):1533-8. PubMed ID: 19020738
[TBL] [Abstract][Full Text] [Related]
18. Sequential chemoimmunotherapy for metastatic melanoma.
Richards JM
Semin Oncol; 1991 Oct; 18(5 Suppl 7):91-5. PubMed ID: 1948135
[TBL] [Abstract][Full Text] [Related]
19. Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma.
Richards JM; Gale D; Mehta N; Lestingi T
J Clin Oncol; 1999 Feb; 17(2):651-7. PubMed ID: 10080611
[TBL] [Abstract][Full Text] [Related]
20. [Therapy of malignant melanoma at the stage of distant metastasis].
Garbe C; Eigentler TK
Hautarzt; 2004 Feb; 55(2):195-213. PubMed ID: 15043023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
